NZ611628A - Use of laquinimod for reducing fatigue, improving functional status, and improving quality of life in multiple sclerosis patients - Google Patents

Use of laquinimod for reducing fatigue, improving functional status, and improving quality of life in multiple sclerosis patients

Info

Publication number
NZ611628A
NZ611628A NZ611628A NZ61162811A NZ611628A NZ 611628 A NZ611628 A NZ 611628A NZ 611628 A NZ611628 A NZ 611628A NZ 61162811 A NZ61162811 A NZ 61162811A NZ 611628 A NZ611628 A NZ 611628A
Authority
NZ
New Zealand
Prior art keywords
laquinimod
improving
functional status
deterioration
multiple sclerosis
Prior art date
Application number
NZ611628A
Other languages
English (en)
Inventor
Nora Tarcic
Dan Bar-Zohar
Dina Kofler
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46162796&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ611628(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of NZ611628A publication Critical patent/NZ611628A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Nutrition Science (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NZ611628A 2010-12-07 2011-12-06 Use of laquinimod for reducing fatigue, improving functional status, and improving quality of life in multiple sclerosis patients NZ611628A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US42074210P 2010-12-07 2010-12-07
US201161542996P 2011-10-04 2011-10-04
PCT/US2011/063460 WO2012078591A1 (en) 2010-12-07 2011-12-06 Use of laquinimod for reducing fatigue, improving functional status, and improving quality of life in multiple sclerosis patients

Publications (1)

Publication Number Publication Date
NZ611628A true NZ611628A (en) 2015-06-26

Family

ID=46162796

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ611628A NZ611628A (en) 2010-12-07 2011-12-06 Use of laquinimod for reducing fatigue, improving functional status, and improving quality of life in multiple sclerosis patients

Country Status (19)

Country Link
US (1) US20120142730A1 (https=)
EP (1) EP2648732A4 (https=)
JP (2) JP2013544887A (https=)
KR (1) KR20130124518A (https=)
CN (1) CN103260624B (https=)
AU (2) AU2011338647A1 (https=)
BR (1) BR112013014061A2 (https=)
CA (1) CA2820586A1 (https=)
CL (1) CL2013001602A1 (https=)
EA (1) EA201390827A1 (https=)
IL (1) IL250726A0 (https=)
MX (1) MX2013006464A (https=)
NZ (1) NZ611628A (https=)
PE (1) PE20140872A1 (https=)
PH (1) PH12013501193A1 (https=)
SG (2) SG10201509831XA (https=)
UA (1) UA111959C2 (https=)
WO (1) WO2012078591A1 (https=)
ZA (1) ZA201304237B (https=)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ567088A (en) * 2005-10-19 2012-06-29 Teva Pharma Crystals of laquinimod sodium, and process for the manufacture thereof
EP2234485B1 (en) 2007-12-20 2013-11-13 Teva Pharmaceutical Industries, Ltd. Stable laquinimod preparations
PL2458992T3 (pl) * 2009-07-30 2016-07-29 Teva Pharma Leczenie choroby Leśniowskiego-Crohna z użyciem lakwinimodu
WO2011019375A1 (en) 2009-08-10 2011-02-17 Teva Pharmaceutical Industries Ltd. Treatment of bdnf-related disorders using laquinimod
DK2542079T3 (da) * 2010-03-03 2014-08-25 Teva Pharma Behandling af reumatoid artritis med en kombination af laquinimod og methotrexat
SG183512A1 (en) * 2010-03-03 2012-09-27 Teva Pharma Treatment of lupus nephritis using laquinimod
WO2012006538A1 (en) 2010-07-09 2012-01-12 Teva Pharmaceutical Industries Ltd. Deuterated n-ethyl-n-phenyl-1,2-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide, salts and uses thereof
CA2851525A1 (en) 2011-10-12 2013-04-18 Teva Pharmaceutical Industries Ltd. Treatment of multiple sclerosis with combination of laquinimod and fingolimod
CN104093310A (zh) 2012-02-03 2014-10-08 泰华制药工业有限公司 拉喹莫德用于治疗一线抗TNFα疗法失败的克罗恩氏病患者的用途
JP6215238B2 (ja) 2012-02-16 2017-10-18 テバ ファーマシューティカル インダストリーズ リミティド Ｎ−エチル−ｎ−フェニル−１，２−ジヒドロ−４，５−ジ−ヒドロキシ−１−メチル−２−オキソ−３−キノリンカルボキサミド、その製剤、および使用
TW201350467A (zh) 2012-05-08 2013-12-16 Teva Pharma Ｎ－乙基－４－羥基－１－甲基－５－（甲基（２，３，４，５，６－五羥基己基）胺基）－２－側氧－ｎ－苯基－１，２－二氫喹啉－３－甲醯胺
TW201400117A (zh) 2012-06-05 2014-01-01 Teva Pharma 使用拉喹莫德治療眼發炎疾病
TW201410244A (zh) 2012-08-13 2014-03-16 Teva Pharma 用於治療ｇａｂａ媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ）
MX2015003608A (es) * 2012-09-27 2015-06-05 Teva Pharma Combinacion de laquinimod y pridopidina para tratar trastornos neurodegenerativos.
BR112015007782A2 (pt) * 2012-10-12 2017-07-04 Teva Pharma laquinimod para reduzir danos talâmicos na esclerose múltipla
EP2916915A4 (en) 2012-11-07 2016-06-22 Teva Pharma LAQUINIMOD AMINE SALTS
BR112015019564A2 (pt) * 2013-02-15 2017-07-18 Teva Pharma tratamento de esclerose múltipla com laquinimod
US20160046582A1 (en) 2013-03-14 2016-02-18 Teva Pharmaceutical Industries Ltd. Crystals of laquinimod sodium and improved process for the manufacture thereof
US20160038435A1 (en) 2013-03-14 2016-02-11 Teva Pharmaceutical Industries Ltd. Transdermal formulations of laquinimod
CA2933380A1 (en) * 2013-12-20 2015-06-25 Esther Lukasiewicz Hagai Use of laquinimod to delay huntington's disease progression
HK1225969A1 (zh) * 2014-01-17 2017-09-22 Teva Pharmaceutical Industries Ltd 利用低剂量的拉喹莫德治疗克隆氏病
WO2015168103A1 (en) * 2014-04-29 2015-11-05 Teva Pharmaceutical Industries Ltd. Laquinimod for the treatment of relapsing-remitting multiple sclerosis (rrms) patients with a high disability status
CN114699409A (zh) * 2014-10-16 2022-07-05 诺华股份有限公司 包含辛波莫德和拉喹莫德的用于治疗多发性硬化症的组合
MX2017008136A (es) 2014-12-22 2018-03-06 Teva Pharmaceuticals Int Gmbh Sal de l-tartrato de pridopidina.
WO2020076809A1 (en) * 2018-10-09 2020-04-16 Medicinova, Inc. Combination of ibudilast and interferon-beta and methods of using same
BR112022001138A2 (pt) * 2019-07-22 2022-03-15 Actelion Pharmaceuticals Ltd Métodos de tratamento de esclerose múltipla
CN110688373A (zh) * 2019-09-17 2020-01-14 杭州绿度信息技术有限公司 一种基于逻辑回归的offset方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20160455T1 (hr) * 2004-09-09 2016-07-15 Yeda Research And Development Co., Ltd. Smjese polipeptida, sastavi koji ih sadrže i postupci za njihovu pripremu, te njihove primjene
US20060205822A1 (en) * 2004-12-22 2006-09-14 Forest Laboratories, Inc. 1-Aminocyclohexane derivatives for the treatment of multiple sclerosis, emotional lability and pseudobulbar affect
US9168286B2 (en) * 2005-10-13 2015-10-27 Human Genome Sciences, Inc. Methods and compositions for use in treatment of patients with autoantibody positive disease
KR20150065951A (ko) * 2006-06-12 2015-06-15 테바 파마슈티컬 인더스트리즈 리미티드 안정한 라퀴니모드 제제
EP2680010A1 (en) * 2007-02-08 2014-01-01 Biogen Idec MA Inc. Nrf2 screening assays and related methods and compositions
JP2012530701A (ja) * 2009-06-19 2012-12-06 テバ ファーマシューティカル インダストリーズ リミティド 多発性硬化症のラキニモドでの治療

Also Published As

Publication number Publication date
EP2648732A4 (en) 2014-04-30
EA201390827A1 (ru) 2013-12-30
WO2012078591A1 (en) 2012-06-14
CN103260624A (zh) 2013-08-21
ZA201304237B (en) 2014-08-27
SG10201509831XA (en) 2015-12-30
CN103260624B (zh) 2015-06-03
AU2011338647A8 (en) 2013-09-05
EP2648732A1 (en) 2013-10-16
KR20130124518A (ko) 2013-11-14
PH12013501193A1 (en) 2013-07-15
BR112013014061A2 (pt) 2016-09-13
WO2012078591A8 (en) 2012-08-02
UA111959C2 (uk) 2016-07-11
MX2013006464A (es) 2013-07-29
SG190449A1 (en) 2013-07-31
IL250726A0 (en) 2017-04-30
JP2013544887A (ja) 2013-12-19
CL2013001602A1 (es) 2013-10-25
AU2017202055A1 (en) 2017-04-20
JP2017095476A (ja) 2017-06-01
US20120142730A1 (en) 2012-06-07
CA2820586A1 (en) 2012-06-14
AU2011338647A1 (en) 2013-07-04
PE20140872A1 (es) 2014-08-09

Similar Documents

Publication Publication Date Title
NZ611628A (en) Use of laquinimod for reducing fatigue, improving functional status, and improving quality of life in multiple sclerosis patients
MX2011013902A (es) Tratamiento de esclerosis multiple con laquinimod.
NZ594056A (en) New stable formulations of recombinant human albumin-human granulocyte colony stimulating factor fusion protein
PH12014502447A1 (en) Use of high dose laquinimod for treating multiple sclerosis
NZ589445A (en) Rasagiline for parkinson's disease modification
HK1221646A1 (zh) 高剂量普利多匹定用於治疗亨廷顿舞蹈症的用途
FI3504187T3 (fi) Pridopidiinin käyttö toiminnallisen heikkenemisen hoitoa varten
NZ600544A (en) Compositions and methods for the treatment of angiogenesis-related eye diseases
NZ595941A (en) Treatment of neurodegeneration and neuroinflammation
RU2014109074A (ru) ИНГИБИТОРЫ ФАННИ-ТОКА (If), ПРЕДНАЗНАЧЕННЫЕ ДЛЯ ПРИМЕНЕНИЯ В СПОСОБЕ ЛЕЧЕНИЯ И ПРЕДУПРЕЖДЕНИЯ СЕРДЕЧНОЙ НЕДОСТАТОЧНОСТИ У КОШАЧЬИХ
WO2011014255A8 (en) Treatment of crohn's disease with laquinimod
NZ602510A (en) Treatment of lupus nephritis using laquinimod
NZ613291A (en) Treatment of cognitive disorders with (r)-7-chloro-n-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide and pharmaceutically acceptable salts thereof
SG150531A1 (en) Use of meloxicam for the treatment of respiratory diseases in pigs
NZ612717A (en) Treatment of pain associated with dislocation of basal endometrium
HK1202776A1 (en) Use of laquinimod for treating crohn's disease patients who failed first-line anti-tnf therapy
MX2009004561A (es) Derivados de pirazolilo con actividad analgesica y utiles en el tratamiento o profilaxis del dolor.
NZ700824A (en) Use of lysosomal acid lipase for treating lysosomal acid lipase deficiency in patients
IN2012DN06616A (https=)
JP2013541583A5 (https=)
JP2013516493A5 (https=)
NZ700924A (en) Dosage regimen for a pi-3 kinase inhibitor
MX350195B (es) Analogos de cistamina para el tratamiento de la enfermedad de parkinson.
MD20140004A2 (en) Deuterated 1-piperazino-3-phenyl-indanes for treatment of schizophrenia
NZ602032A (en) Oral b12 therapy

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 06 DEC 2016 BY DENNEMEYER + CO

Effective date: 20151124

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 06 DEC 2017 BY DENNEMEYER + CO

Effective date: 20161129

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 06 DEC 2018 BY DENNEMEYER + CO

Effective date: 20171122

LAPS Patent lapsed